Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Pruthi on What She Learned From the Flaxseed Trial

August 1st 2011

Dr. Sandhya Pruthi from the Mayo Clinic in Minnesota on What She Learned From the Flaxseed Trial

Sentinel Lymph Node Test Has No Effect on Overall Survival in Women With Early-Stage Breast Cancer

July 28th 2011

It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.

Dr. Pruthi Examines Options Available for Hot Flashes

July 25th 2011

Dr. Sandya Pruthi from the Mayo Clinic in Minnesota Examines the Options Available for Hot Flashes after the failure of flaxseed

Dr. Kris Explains the Use of Gene Signatures

July 25th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used

Ob-Gyn Physicians Support Mammograms Starting at Age 40

July 22nd 2011

The American College of Obstetricians and Gynecologists this week recommended annual mammography screenings for women starting at age 40.

Avastin Still Recommended by NCCN for Use Against Metastatic Breast Cancer

July 21st 2011

The NCCN voted to maintain the current recommendation and position on Avastin (bevacizumab) in its treatment of metastatic breast cancer.

Iniparib Fails to Improve Survival as Part of Chemotherapy in Triple-Negative Breast Cancer

July 21st 2011

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

FDA Advised Not to Approve Dapagliflozin for Diabetes

July 20th 2011

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Pruthi on the Flaxseed for Hot Flashes Trial Results

July 19th 2011

Dr. Sandhya Pruthi from the Mayo Clinic Explains the Flaxseed for Hot Flashes Trial Results

Trastuzumab and Chemotherapy Prolong Survival in Patients With Breast Cancer and CNS Metastases

July 18th 2011

Treatment with Herceptin, chemotherapy, or surgery extended the lives of patients with HER2-positive MBC following a diagnosis of CNS metastases.

Interim Safety Data Compared in Ixabepilone TITAN Trial

July 18th 2011

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Tripathy on Breast Cancer with Bone Metastases

July 16th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

BOLERO-2 Halted After Positive Interim Analysis

July 13th 2011

A phase III study of Afinitor (everolimus) tablets combined with exemestane in women with breast cancer revealed that the regime significantly extended PFS.

Study Shows Estrogen Not the Only Hormone Feeding Tumors in Breast Cancer

July 13th 2011

Although researchers know that estrogen plays a role in most cases of breast cancer, they don't fully understand how.

Dr. Whelan on the Women the MA.20 Trial Benefits

July 11th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits

Dr. Whelan Discusses the MA.20 Trial's Survival Findings

July 8th 2011

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Comorbid Conditions Threaten Breast Cancer Survivors

July 1st 2011

Breast cancer survivors age 66 and older are more likely to die of cardiovascular disease (CVD) than they are of the cancer itself.